



OTC Pink Basic Disclosure Guidelines

Quarter Ending March 31, 2017

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Current Name: Predictive Technology Group, Inc. – 07/16/2015

Former Name: Global Enterprises Group, Inc.- 03/12/2014

2) Address of the issuer's principal executive offices

Company Headquarters

Address 1: **2749 East Parleys Way, Suite 101**

Address 2: **Salt Lake City, UT 84109**

Address 3: Phone: **7573066090**

Email: **info@predictivetechnologygroup.com**

Website(s): **www.predictivertechnologygroup.com**

IR Contact

Address 1: **YES INTERNATIONAL**

Address 2: **3419 Virginia Beach Blvd, Unit 252**

Address 3: **Virginia Beach, VA 23452**

Phone: **7573066090**

Email: **rich@yesinternational.com**

Website(s): **www.yesinternational.com**

3) Security Information

Trading Symbol: **PRED**

Exact title and class of securities outstanding: **900,000,000 shares Common Stock; par value \$0.001**
10,000,000 shares Preferred par value \$0.001

CUSIP: 74039H102

Par or Stated Value: 0.001 Common

Total shares authorized: 900,000,000 as of: March 31, 2017

Total shares outstanding: 182,884,682 as of: March 31, 2017

Additional class of securities (if necessary):

Trading Symbol: N/A

Exact title and class of securities outstanding: 10,000,000 shares preferred par value \$0.001

CUSIP: none

Par or Stated Value: \$ 0.001

Total shares authorized: 10,000,000 as of: March 31, 2017

Total shares outstanding: -0- as of: March 31, 2017

Transfer Agent

Name: **Transfer Online, Inc.**

Address 1: **512 SE Salmon Street**

Address 2: **Portland, OR 97214**

Address 3: **www.transferonline.com**

Phone: **Phone #503-227-2950**

Is the Transfer Agent registered under the Exchange Act?* Yes: No:

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

NONE

Describe any trading suspension orders issued by the SEC in the past 12 months.

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On April 12, 2016 the Company announced finalization of the acquisition of ReNovo Biotech, Inc. for 9,500,000 shares of Common Stock restricted Rule 144 shares.

On January 10, 2017, the Company announced the acquisition of US patent application 62/295,042 direct to the practice of "cleaning" stem cells of a predetermined disease associated marker via the "Clustered Regularly Interspaced Short Palindromic Repeats --CRISPR" process and administering the stem cells to the patient. 500,000 shares of Common Stock restricted Rule 144 shares were issued as part of the acquisition.

On July 19, 2016 the Company acquired, through issuance of 300,000 shares Common Stock of restricted Rule 144 shares for protocols related to the operation and management of a CLIA lab and related genetic tests.

On August 1, 2016, the Company acquired notes receivable from debt holders of Juneau Biosciences in the amount of \$3,103,519 bearing interest at the rate of 12% per annum through the issuance of 6,207,039 shares of Common Stock restricted Rule 144 shares.

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

During the past twelve months the Company issued 2,633,920 shares of Common Stock restricted Rule 144 shares at a share price of \$.50 per share of Common Stock and 2,633,920 warrants to purchase shares of Common Stock restricted Rule

144 shares with an exercise price of \$.50 per share of Common Stock with an expiration date of Aug 1, 2021.

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otcq.com in the field below.

Quarterly and Year to Date Financial Statements for period ending March 31, 2017 are incorporated as reference and filed on OTC MARKETS' OTCIQ.COM on May 15, 2017.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

- A. a description of the issuer's business operations;

Predictive Technology Group, Inc., a publicly traded entity with stock symbol, PRED which traded on the OTC, looks to improve lives by indentifying, developing, acquiring and commercializing medical apparatuses and treatments that address human medical needs.

Predictive Technology Group, Inc., through its wholly owned subsidiaries, Predictive Therapeutics ("PRx") and Predictive Biotech, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics.

PRx has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease's onset and progression.

PRx uses this information as the cornerstone in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.

PRx' utilization of molecular diagnostics focuses on the analysis of genes and their mutations to assess a patient's inherited risk for developing a particular disease and its progression (predictive healthcare). Additionally, PRx believes that advances in the emerging field of molecular diagnostics will improve the ability to

determine which patients are subject to a greater risk of developing disease and who therefore would benefit from preventive therapies. Molecular diagnostic products may also guide a patient's healthcare to ensure the patient receives the most appropriate treatment at the most appropriate time (i.e., most effective).

PRx is well positioned with short and long-term assets in its pipeline to be a leader in the future of preventative, personalized and precision healthcare. Current trends in medicine lie in the creation of new classes of drugs that treat the underlying cause, not just the symptoms, of disease and may be useful in disease prevention. By understanding the genetic basis of disease and by working with strategic partners, PRx believes that it will be able to develop drugs and treatment protocols that are more effective, resulting in better patient outcomes at significantly lower costs.

PRx' development expertise is uniquely enhanced by its strategic development collaborations. Some of those development assets are included below:

- 600,000 DNA samples in library as a result of a birth defect or serious maternity issue
- HIPAA compliant
- Collected from most genetically diverse population in U.S.
- Believed to be largest DNA library in world related to women's health
- Corresponding proprietary genealogy database developed from over 50,000 public sources
- Gen DB – Proprietary genealogy database used to accelerate genetic discoveries

NHP-07 – First pharmaceutical/therapeutic candidate to be developed by PRx. Management believes NHP-07 with EndoRisk® as a companion diagnostic/prognostic is the only treatment protocol that can prevent development of endometriosis and, in women experiencing advanced stages of endometriosis NHP-07, stop the progression of the disease while suppressing the debilitating symptoms.

-Approximately 7.5 million women suffer from endometriosis in the United States with only 2.5 million women currently diagnosed

**Approximately 70 million women world wide are symptomatic of endometriosis
Greater than \$1Billion annual US market**

-Tremendous need for new more effective/lower side-effect therapeutics to meet this unmet demand

-Suppresses the symptoms of endometriosis in women diagnosed with endometriosis

-Prevents the development of the disease

-Combination of two or more existing FDA-approved compounds, whose safety has already been established over decades

-Coupled with EndoRisk® as a companion diagnostic NHP-07 can be given prior to development of endometriosis or becoming symptomatic to prevent the disease altogether

-Patent issued October 2015 for combination of progesterone and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

-Patent issued October 2015 for combination of progesterone and cannabinoids

-On June 21, 2016, the company, announced that the United States Patent and Trademark Office (USPTO) has granted a fundamental patent (US Patent 9,370,431) that covers the practice of administering ANY spine deformation therapeutics to a patient having a spine deformation altered risk associated biomarker.

- On January 10, 2017, the Company, announced the acquisition of US patent application 62/295,042 direct to the practice of "cleaning" stem cells of a predetermined disease associated marker via the "Clustered Regularly Interspaced Short Palindromic Repeats --CRISPR" process and administering the stem cells to the patient.

On January 12, 2017, the Company, announces the issuance of US patent 9,434,991 direct to a method for performing an Advanced Reproductive Therapy ("ART").

Predictive Biotech develops and commercializes minimally manipulated allograft products from umbilical cord and placental tissue.

- **Human Cell and Tissue Products include:**

- **CoreCyte™ Allogenic Human Umbilical Cord Tissue Mesenchymal Stem Cell Product:** This product is a potential substitute for Autologous MSC products derived from human adipose or bone marrow aspirate concentrate.
- **PolyCyte™ Allogenic Human Umbilical Cord Tissue Matrix Product:** This product contains proteins, Cytokines, Hyaluronic Acid. This product can be used as a substitute for synthetic Hyaluronic Acid products.
- **AmnioCyte™ Allogenic Amniotic Liquid Suspension Product:** This product contains proteins, Cytokines, Hyaluronic Acid. This product can be used as a substitute for synthetic Hyaluronic Acid products.
- **AmnioCyte Plus™ Amniotic Membrane Product** used as an anti-adhesion barrier for spinal procedures and for wound healing to reduce pain, scarring and increase healing time for burn victims and diabetic ulcers.

Genetic diagnostics do not require approval by the FDA in order to go to market if the tests are Laboratory Developed Tests ("LDTs"), which are regulated under the Clinical Laboratory Improvement Amendments ("CLIA"). It is estimated that of the 2,000 genetic tests commercially available less than a dozen were reviewed by FDA. The American Clinical Laboratory Association ("ACLA") filed a citizen petition on June 4, 2013 challenging the FDA's authority to regulate LDTs as medical devices under the federal Food, Drug, and Cosmetic Act (FDCA). The ACLA stated, "CLIA allows laboratories the flexibility to develop and validate LDTs quickly to respond to public health needs." The ACLA also wrote, "Laboratories are able to update LDTs regularly as medicine advances, so that patients have access to the most advanced testing." LDTs are laboratory services, not products, and are not distributed, nor delivered or placed into market, noted the petition. "They are proprietary procedures for performing a diagnostic test using reagents and laboratory equipment, essentially know-how."

Proven and Experienced Team – An experienced team that has completed similar product ventures from conception to commercialization through internal sales and marketing and/or major strategic partnerships. The key executives have a track record of successfully developing and marketing high volume products in the healthcare field. As a result, PRED will be able to benefit from and leverage valuable relationships with industry leaders. Discussions have already commenced with significant companies that have major women's health franchises.

Predictive Technology Group, Inc. through its acquisitions of both Predictive Therapeutics, LLC, Predictive Biotech, Inc. and LifeCode Genetics, Inc. has a number of patents and licenses agreements (notes to the "Financial Statements" has a complete list).

Predictive Technology Group, Inc. owns 12% (approx.) of Juneau Biosciences, LLC which came about through the aforementioned acquisition of LifeCode Genetics, Inc.

B. Date and State (or Jurisdiction) of Incorporation:

August 25, 2005 State of NEVADA

C. the issuer's primary and secondary SIC Codes;

Primary S.I.C- 2835

Secondary SIC- 8731

D. the issuer's fiscal year end date;

June 30

E. principal products or services, and their markets;

Predictive Technology Group, Inc. (PRED) has thru wholly owned subsidiaries, Predictive Therapeutics, LLC ("PRx"), Predictive Biotech, Inc. and LifeCode Genetics, is organized to develop, commercialize, acquire and invest in technologies involved in novel molecular diagnostic and therapeutic products in healthcare.

The PRx and Predictive Biotech subsidiaries intend to revolutionize the treatment of serious, chronic and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. PRx and Predictive Biotech have developed and/or acquired a pipeline of products. These proprietary technologies can open a window into the origin of human disease and the role that genes and their related proteins play in the disease's onset and progression. PRx uses genetic information as the cornerstone in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and treat the disease.

The LifeCode Genetics, Inc. wholly owned subsidiary develops and commercializes gene based diagnostics treatments and therapies.

On April 12, 2016, the Company announced the acquisition of ReNovo Biotech, Inc. as its wholly owned subsidiary. The acquisition provides the Company access to ReNovo Biotech's cellular, tissue, biomaterial and regenerative medicine products and product candidates. Also, the Company will gain access to ReNovo's distribution channels, including access to customers from the recent signing of several private label agreements. This subsidiary will be operated under the name Predictive Biotech, Inc.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Corporate Office-Predictive Therapeutics: 2749 East Parleys Way, Suite 101, Salt Lake City, UT 84109, \$9,700.00 per month, on a month to month lease, includes administrative offices, lab space, lab benches and lab equipment.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

- A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Mr. Merle Ferguson is Chairman and Secretary

Mr. Bradley Robinson is President / Director

- B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None

9) **Third Party Providers**

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Name: **Vern Norviel**

Firm: **Wilson Sonsini Goodrich & Rosati**

Address 1: **650 Page Mill Road**

Address 2: **Palo Alto, CA 94304-1050**

Phone: **650-493-9300**

Email: **vnorniel@wsgr.com**

Accountant or Auditor

Name: KIRK M. GIBB, CPA

Firm: **SADLER, GIBB & ASSOCIATES, LLC**

Address 1: **2455 East Parleys Way, Suite 320**

Address 2: **Salt Lake City, Utah 84109**

Phone: **801-783-2950**

Email: _____

Investor Relations Consultant

Name: **Richard Kaiser**

Firm: **YES INTERNATIONAL**

Address 1: **3419 Virginia Beach Blvd, Unit 252**

Address 2: **Virginia Beach, VA 23452**

Phone: **7573066090**

Email: **rich@yesinternational.com**

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

Name: _____

Firm: _____

Address 1: _____

Address 2: _____

Phone: _____

Email: _____

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Merle Ferguson certify that:

1. I have reviewed this Quarterly disclosure document of Predictive Technology Group, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/15/2017

/s/ Merle Ferguson

Chairman/ Secretary / Treasurer